Hemogenyx Pharmaceuticals PLC Collaboration with Johnson & Johnson Innovation (9667D)
October 15 2018 - 2:00AM
UK Regulatory
TIDMHEMO
RNS Number : 9667D
Hemogenyx Pharmaceuticals PLC
15 October 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Immugenyx Enters Collaboration with Johnson & Johnson
Innovation
Hemogenyx Pharmaceuticals Plc (LSE: HEMO; Hemogenyx), the
biopharmaceutical group developing new therapies and treatments
designed to transform bone marrow transplantation for the treatment
of blood diseases, announces that its wholly owned subsidiary,
Immugenyx, LLC ("Immugenyx"), has entered into a collaboration
agreement with Janssen Research & Development, LLC ("Janssen"),
one of the Janssen Pharmaceutical Companies of Johnson &
Johnson. The agreement was facilitated by Johnson & Johnson
Innovation LLC.
Immugenyx will collaborate with Janssen on the development of a
model of systemic lupus erythematosus (SLE), the most common form
of Lupus, using its advanced hematopoietic chimeras (AHC). AHC, a
new type of humanised mouse with a functional human immune system,
is being developed by Immugenyx as an in vivo platform for disease
modelling and drug development.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx,
commented: "As a company committed to the development of novel
therapeutic products for patients suffering from blood and severe
autoimmune diseases, we are pleased to partner with Janssen, a
world leader in the discovery and development of therapeutics for
autoimmune diseases."
According to the terms of the agreement, Immugenyx will
collaborate with Janssen on research activities that are determined
by a mutually approved research plan. Immugenyx shall own the
humanised mouse model of Lupus to be developed in collaboration
with Janssen. Immugenyx shall grant to Janssen and its Affiliates a
perpetual, irrevocable, non-exclusive, fully-paid-up, transferable,
worldwide, license to use the Lupus model solely for their own
internal research and product development purposes. Financial terms
of the collaboration are not disclosed.
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer Via Walbrook PR
& Co-Founder
Sir Marc Feldmann, Executive Chairman
Northland Capital Partners Limited Tel: +44 (0)20 3861 6625
Matthew Johnson, Vadim Alexandre, Dugald J
Carlean
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
Walbrook PR (UK Media & Investor Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Relations)
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals PLC. is a publicly traded company
(LSE: HEMO) headquartered in London, with its wholly owned US
operating subsidiary, Hemogenyx LLC, located in Brooklyn, New York
at its state- of- the- art research facility ("Hemogenyx").
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risk of toxicity and death that are associated with bone marrow
transplantation, however, have meant that the procedure is used
only as a last resort and its use is restricted. Hemogenyx's
technology has the potential to enable many more patients suffering
from devastating blood diseases, such as leukemia and lymphoma, as
well as severe autoimmune diseases, such as multiple sclerosis,
aplastic anemia and systemic lupus erythematosus (Lupus), to
benefit from bone marrow transplantation.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCZMMMGZDDGRZM
(END) Dow Jones Newswires
October 15, 2018 02:00 ET (06:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024